Alnylam Pharmaceuticals | ALNY - Stock


Alnylam Pharmaceuticals reported $82.72M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 34.67M 5.57M Dec/2025
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
Alnylam Pharmaceuticals USD 82.72M 7.34M Dec/2025
Amgen USD 6.22B 121M Dec/2025
Arrowhead Research USD -173.08M 173.08M Dec/2024
BioCryst Pharmaceuticals USD 5.23M 188K Sep/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Incyte USD 101.06M 17.61M Dec/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Moderna USD 332M 92M Sep/2025
Neurocrine Biosciences USD 69M 300K Dec/2025
Novartis USD 6.42B 114M Sep/2025
PTC Therapeutics USD 79.65M 26.96M Dec/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
Takeda JPY 1.41T 107.71B Dec/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025